Amgen (AMGN) Cash from Operations (2009 - 2026)
Amgen (AMGN) posted quarterly Cash from Operations of 2189000000.0 for Q1 2026, up 57.37% year-over-year from 1391000000.0 in Q1 2025, and up 36.56% quarter-over-quarter from 1603000000.0 in Q4 2025.
Amgen (AMGN) Cash from Operations (2009 - 2026) Analysis & Trends
Amgen's Cash from Operations history runs 18 years deep, the most recent figure standing at 2189000000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 57.37% year-over-year to 2189000000.0; the TTM figure through Mar 2026 stood at 10756000000.0 (down 11.78% YoY), while the FY2025 annual figure was 9958000000.0, down 13.33% from the prior year.
- Cash from Operations for Q1 2026 stood at 2189000000.0, up from 1603000000.0 in the prior quarter.
- The five-year high for Cash from Operations was 4771000000.0 in Q4 2024, with the low at 538000000.0 in Q4 2023.
- The 5-year median for Cash from Operations is 2280000000.0 (2025), against an average of 2460529411.76.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations sank 79.69% in 2023, then soared 786.8% in 2024.
- Amgen's Cash from Operations stood at 2649000000.0 in 2022, then tumbled by 79.69% to 538000000.0 in 2023, then jumped by 786.8% to 4771000000.0 in 2024, then tumbled by 66.4% to 1603000000.0 in 2025, then soared by 36.56% to 2189000000.0 in 2026.
- Business Quant data shows AMGN's Cash from Operations at 2189000000.0 in Q1 2026, 1603000000.0 in Q4 2025, and 4684000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 8.62 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.44 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 5.37 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.88 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 4.00 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.57 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 835.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.00 Bn |
| Jun 30, 2026 | 4.00 Bn |
| Mar 31, 2026 | 2.19 Bn |
| Mar 31, 2026 | 2.19 Bn |
| Dec 31, 2025 | 1.60 Bn |
| Dec 31, 2025 | 1.60 Bn |
| Sep 30, 2025 | 4.68 Bn |
| Sep 30, 2025 | 4.68 Bn |
| Jun 30, 2025 | 2.28 Bn |
| Jun 30, 2025 | 2.28 Bn |
| Mar 31, 2025 | 1.39 Bn |
| Mar 31, 2025 | 1.39 Bn |
| Dec 31, 2024 | 4.77 Bn |
| Dec 31, 2024 | 4.77 Bn |
| Sep 30, 2024 | 3.57 Bn |
| Sep 30, 2024 | 3.57 Bn |
| Jun 30, 2024 | 2.46 Bn |
| Jun 30, 2024 | 2.46 Bn |
| Mar 31, 2024 | 689.00 Mn |
| Mar 31, 2024 | 689.00 Mn |